Clinical Trials
23 trialsNCT07570173 2026-06-05
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT05139017 2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT04442022 2026-05-06
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2/3 Active not recruiting
NCT06125951 2026-04-23
XanaMIA
Actinogen Medical
Phase 2/3 Active not recruiting
NCT04817761 2026-02-18
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Servier
Phase 2/3 Terminated
NCT02763319 2025-07-17
B-MIND
Incyte Corporation
Phase 2/3 Completed
NCT04851717 2025-07-01
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
Acacia Pharma Ltd
Phase 2/3 Active not recruiting
NCT05664217 2025-02-13
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Therapeutics
Phase 2/3 Terminated
NCT06548347 2024-08-12
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 2/3 Not yet recruiting
NCT03801525 2024-04-19
ULTRA-V
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT00877656 2024-03-18
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
Emergent BioSolutions
Phase 2/3 Completed
NCT04145531 2023-11-18
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Jazz Pharmaceuticals
Phase 2/3 Completed
NCT04021082 2023-02-21
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Alexion Pharmaceuticals, Inc.
Phase 2/3 Withdrawn
NCT02793583 2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT01518517 2022-02-02
GRASPIVOTALL
ERYtech Pharma
Phase 2/3 Completed
NCT00003338 2021-08-16
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 2/3 Unknown
NCT00967343 2021-06-14
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
Phase 2/3 Terminated
NCT02910063 2021-01-13
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Amgen
Phase 2/3 Completed
NCT01197560 2019-11-25
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Celgene
Phase 2/3 Completed
NCT00349518 2016-02-17
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
Phase 2/3 Withdrawn
NCT02072330 2014-02-26
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
Takeda
Phase 2/3 Completed
NCT01277172 2011-01-14
TREND
Probiomed S.A. de C.V.
Phase 2/3 Unknown
NCT00045877 2006-02-06
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
Chiron Corporation
Phase 2/3 Completed